RxDoctor Payments Data

Asia Work, APRN

Family · Louisville, KYNPI 1316135684

Payments from drug & device makers

$3,846in general payments, 2019–2025

Across 120 payments — averaging $32.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$803
  • CSL Behring$629
  • Optinose US, Inc.$438
  • Sanofi$331
  • Biohaven Pharmaceutical Holding Company Ltd.$251
  • Regeneron Healthcare Solutions, Inc.$238
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,846100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,846 in reported general payments places this provider in the 85th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$69,412
Medicare patients
468
Services billed
1,170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Epinephrine12$2,820
Ofloxacin25$1,470
Ipratropium Bromide45$1,285
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth12$1,284
Azelastine Hcl73$1,259
Tobramycin-DexamethasoneTobramycin/Dexamethasone16$805
Montelukast Sodium95$529
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav22$189
Fluticasone Propionate12$182
Mupirocin28$182
Omeprazole25$160
Methylprednisolone30$134
Triamcinolone Acetonide44$131
Levothyroxine Sodium14$44

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USAEpinephrine$54$2,82012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,374 family providers in Kentucky.

Other family in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →